Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Royalty Pharma plc

http://www.royaltypharma.com

Latest From Royalty Pharma plc

BioCryst Halts Trials For BCX9930 Due To Safety Concerns

Biotech stops enrollment in three Phase II studies of oral Factor D inhibitor BCX9930 after seeing elevated creatinine levels. The halt is voluntary, and enrolled patients can continue dosing, BioCryst says.

Clinical Trials Drug Safety

Finance Watch: Morningside Launches Adiso With More Than $60m In Early Funding

Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations. 

Financing Innovation

Zimmer Biomet Spin-Off’s Share Price Plummets

The share price for ZimVie, Zimmer Biomet’s spinal and dental spin-off company, dropped following its launch on NASDAQ.

Financing Dental Oral

Ipsen Seeks Success Outside Big Pharma's Hunting Grounds

David Loew has assembled a strong business development team which secured seven licensing pacts in 2021 and the Ipsen CEO tells Scrip that this year should see more of the same.

Business Strategies Deals
See All

Company Information

  • Industry
  • Miscellaneous
  • Other Names / Subsidiaries
    • Cypress Bioscience, Inc. (Cellatope Corporation
    • Proprius Pharmaceuticals, Inc.)
    • Ramius LLC
    • Royalty Pharma AG
UsernamePublicRestriction

Register